NCT00063973 - Cilengitide in Treating Children With Refractory Primary Brain Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

March 31, 2008

Conditions

Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma

Interventions

DRUG

cilengitide

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

38105

Pediatric Brain Tumor Consortium, Memphis

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH